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Ischemia and lung cancer model
Neutrophil elastaseThe aimof this studywas to investigate the angiogenic effects of curcumin on an ischemia and lung cancermodel.
To induce ischemia combined with lung cancer models, unilateral femoral arteries of C57BL/6 mice were
disconnected on one side of the mouse and Lewis lung carcinoma (LLC) cells were xenografted on the opposite
side. Angiogenic effects and underlying mechanisms associated with curcumin were investigated. Molecular
target(s), signaling cascades and binding afﬁnities were detected byWestern blot, two-dimensional gel electro-
phoresis (2-DE), computer simulations and surface plasmon resonance (SPR) techniques. Curcumin promoted
post-ischemic blood recirculation and suppressed lung cancer progression in inbred C57BL/6mice via regulation
of the HIF1α/mTOR/VEGF/VEGFR cascade oppositely. Inﬂammatory stimulation induced by neutrophil elastase
(NE) promoted angiogenesis in lung cancer tissues, but these changeswere reversedby curcumin through direct-
ly reducing NE secretion and stimulating α1-antitrypsin (α1-AT) and insulin receptor substrate-1 (IRS-1)
production.Meanwhile, curcumin dose-dependently inﬂuenced endothelial cells (EC) tube formation and chick-
en embryo chorioallantoic membrane (CAM) neovascularization. Curcumin had opposite effects on blood vessel
regeneration under physiological and pathological angiogenesis, whichwas effected through negative or positive
regulation of the HIF1α/mTOR/VEGF/VEGFR cascade. Curcumin had the promise as a new treatmentmodality for
both ischemic conditions and lung cancer simultaneously in the clinic.
© 2014 Elsevier B.V. All rights reserved.sis;α1-AT,α1-antitrypsin; Akt,
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Angiogenesis inhibition elicits detrimental effects on tumor prolifer-
ation [1], whereas revascularization is recognized as a better choice for
ischemic disorders [2–5]. Unfortunately, unselective stimulation of vas-
cular endothelial cells (EC) results in angiogenic problems that can lead
to carcinogenesis, inﬂammation or hypertension [6]. With the increase
of the aging population, concerns have arisen recently for individuals
with multiple diseases. One important current area of concern is the
need for newknowledge regarding the clinicalmanagement of ischemic
insult and lung cancer occurring in the same patient at the same time.
Thus, novel agents that promote angiogenesis in response to ischemic
ailments and block malignant tumor growth are urgently needed [7].
Owing to reduce side effects comparedwith some conventional che-
motherapy, plant-derived ingredients have been extensively used
against malignancies [8]. They are recommended as a feasible therapy
for advanced cancer in combination with radiation therapy. Curcumin,
a dietary pigment in curry, has been characterized as benign and well
tolerated even at extremely high doses [9]. It has also been proposed
as a multitarget drug candidate and used as a template for drug design
[10,11]. Conclusive evidence regarding the beneﬁcial signiﬁcance of
curcumin as a vascular-promoting compound against ischemic insult
has been reviewed [12,13]. As well, curcumin has been shown to exert
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noid crystic carcinoma, lung cancer and breast cancer [14–18]. Although
the multifunctional nature of curcumin towards ischemic conditions or
cancer has been well documented individually, the opposite angiogenic
effects of curcumin have not been studied simultaneously in the same
model. Recently, neutrophil elastase (NE) was reported to be a pro-
inﬂammatory cytokine associated with cancer initiation and progres-
sion [19]. Endogenous NE could potentially accelerate blood vessel re-
generation in malignant disease [20]. Physiological production of NE
was principally stimulated by neutrophils or alveolar macrophages,
and eliminated by α1-antitrypsin (α1-AT) [21]. The decreased α1-AT
might come from cancer tissues, from which endogenous NE was se-
creted [22,23].
The purpose of our present study is to gain a further insight into the
dual angiogenic effect of curcumin in a combined ischemic insult and
Lewis lung cancer (LLC) model, and to investigate if the presence of
NE in the LLC tissue resulted in the opposite regulation of HIF1α/
mTOR/VEGF/VEGFR cascade in this model. A better understanding of
the multiple functions of curcumin may shed new light on the simulta-
neous clinical management of ischemic illnesses and lung cancer.
2. Materials and methods
2.1. Cell culture and ethics statement
The in vitro experiments on human umbilical vein endothelial cells
(HUVEC) complied with the principles outlined in the Declaration of
Helsinki [24]. After obtainingwritten informed consent, HUVECwas iso-
lated fromhumanumbilical cord fromhealthy volunteers according to a
protocol approved by the Ethics Review Board of the Hospital of Beijing
Obstetrics and Gynecology Hospital in China. Cells were taken from the
primary culture and incubated in epithelial cell conditioned medium
(ECCM, GIBCO-BRL, Grand Island, NY, USA) basal media supplemented
with growth supplements including 20% fetal bovine serum (FBS,
Hyclone, Logan, UT, USA), 40 units/mL heparin (Inalco Spa, Milano,
Italy), 50 μg/mL Endothelial Cell Growth Supplement (ECGS, GIBCO-
BRL, Grand Island, NY, USA), 2 mM L-glutamine, 0.4 units/mL insulin,
100 units/mL penicillin and 100 μg/mL streptomycin (Biodee Biotech-
nology Co., Beijing, China) in a humidiﬁed incubator (Sanyo Electric
Co., Ltd., Tokyo, Japan) with 5% CO2 at 37 °C.
For in vivo study, the LLC cell line was purchased from Cell Resource
Center of Peking UnionMedical College (Beijing, China) andmaintained
in Dulbecco's modiﬁed Eagle's medium (DMEM, GIBCO-BRL, Grand Is-
land, NY, USA) with 10% FBS, 100 units/mL penicillin and 100 μg/mL
streptomycin. Cells were maintained at 37 °C with 5% CO2 and proper
humidity.
2.2. Ischemia and LLC mice model
Experimental animal facilities and animal experiments were carried
out in strict accordance with the European Community guidelines for
the use of experimental animals and approved by the Peking University
Committee on Animal Care and Use (Permit Number: IRB00001052-
5135). All surgeries were performed under deep anesthesia with 20%
sodium pentobarbital (Sagatal, Rhone Merieux Ltd., Harlow, Essex,
UK), and all efforts were made to minimize animal suffering.
Wild-type C57BL/6 femalemiceweighing 18–20 gwere provided by
Peking University Health Science Center Institutional Animal Care
(Grade II, Certiﬁcate No. 11-00-0004). Ischemia combined with LLC
tumor models were established as previously described [25]. LLC
tumor tissue (tumor (g): physiological saline (mL)= 1:3, w/v) was ho-
mogenized and 0.2 mL of the suspension (approximately 6 × 106 cells)
was injected subcutaneously (s.c.) into the right ﬂank fold region of the
mouse with the left femoral arteries disconnected on the same day.
Mice (n = 8–10 per group) were randomly divided into three groups
and saline (vehicle), 100 or 300 mg/kg curcumin (purity ≥ 98.0%,Sigma-Aldrich, St. Louis, MO, USA) was administrated every day. On
day 22, micewere killed by decapitation 30min under deep anesthesia.
Ischemic muscles and lung cancer tissues were rinsed with chilled
PBS twice, embedded in an optimal cutting temperature compound
(Tissue-Tek, Miles Scientiﬁc, Naperville, IL, USA) for immunostaining
assay or frozen in liquid nitrogen for Western blot, real-time PCR,
ELISA and LC-MS/MS analysis. All sampleswere stored at−80 °C before
use.
2.3. Laser Doppler analysis
Mice were placed ventral side up under general anesthesia. Limbs
were immobilized and scanned using a laser-Doppler blood-ﬂow Imag-
er (PeriScan PIM3, Perimed, Stockholm, Sweden). Measurements were
done immediately after femoral artery and tumor implantation surgery
at 7, 14 and 21 days on mice with or without curcumin treatment. The
relative morphology of the perfusion data was photographed and the
blood ﬂow recovery index was calculated according to the formula:
blood ﬂow recovery index = [blood ﬂow in the ischemic hind limb
(left)/blood ﬂow in the normal limb (right)] ∗ 100%. To determine the
reproducibility of measurements, scans were performed in triplicate
and the results of six or eight independentmicewere used for statistical
analysis.
2.4. Immunohistochemistry
An immunohistochemistry assay formicrovessel density (MVD)was
performedusingCD31 (1:1000, Cell Signaling, Beverly,MA, USA) as pre-
viously described [26]. Tissues were harvested, and embedded in an op-
timal cutting temperature compound. Frozen tissue sections of 6 μm
thick were incubated at 4 °C for 12 h with CD31 primary antibody.
Sections were rinsed 3 times with phosphate-buffered saline (PBS)
and incubated for 10 min in bovine serum albumin (BSA, Hyclone,
Logan, UT, USA) to block the nonspeciﬁc proteins. After incubating
with the secondary antibody used for CD31 (peroxidase-conjugated
goat anti-mouse IgG) for 1 h at room temperature, slides were counter-
stained with diaminobenzidine and photographed. MVD (%) was calcu-
lated from the ratio of CD31 positive staining area (positive brown
stain) to the total observation area in the viable region. Six ﬁelds per
section (0.5 mm2) were randomly analyzed and the positive staining
areas were calculated using Image-Pro Plus (Media Cybernetics, Silver
Spring, MD, USA).
2.5. Capillary-like tube formation assay
96-well plates (Corning Costar Corp., Cambridge, MA) were coated
with 50 μL of matrigel (BD Biosciences, Franklin Lakes, NJ) and incubat-
ed at 37 °C for 30 min [27]. HUVEC was transplanted to the 96-well
plates with a destiny of 1 × 105 cells/well. Curcumin dissolved in low
serummedium (1% FBS)was added to eachwell at a ﬁnal concentration
of 0.1, 0.3, 1, 3 and 10 μM. After 4 h of incubation, tubemorphology was
recorded. Each experiment was repeated in triplicate and the tube
lengthwas assessed by Image-Pro Plus 6.0 software (Media Cybernetics,
Silver Spring, Maryland, USA).
2.6. Chicken chorioallantoic membrane (CAM) assay
Speciﬁc-pathogen-free (SPF) Leghorn fertile chicken eggs (Beijing
Merial Vital Laboratory Animal Technology Co. Ltd., Beijing, China)
were obtained from 40 weeks old Single CombWhite Leghorn chickens
and maintained in a humidiﬁed environment at 37.5 °C until 6 days of
incubation [28]. A holewith a diameter of 10 × 10mmwas subsequent-
ly broken and continued to incubate for another 1 day. On day 7,
curcumin (0, 0.3, 1, 3, 10 and 30 μM) dissolved in DMEM was then
added to a microbial testing disk and placed onto CAM. After 72 h of in-
cubation, the digitized CAM images were recorded.
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Genes associated with ischemia and lung cancer were screened from
Online Mendelian Inheritance in Man (OMIM, http://www.ncbi.nlm.nih.
gov/omim), Genetic Association Database (GAD, http://www.
geneticassociationdb.nih.gov/) and GeneCards (http://www.genecards.
org). To infer a network-based pathway analysis of ischemia and lung
cancer, Agilent LitSearch tool in Cytoscape environment (http://www.
cytoscape.org)was utilized for gene excavation [29]. For Network Analyz-
er application, self-loops and duplicated edges were ignored.
2.8. Pathways enrichment analysis
After intersecting with Network Merge plugin, predominant gene
regulatory networks (GRNs) associated with ischemia and lung cancer
were clusteredbymolecular complexdetection (MCODE) algorithm[30].
For pathways enrichment analysis, ToppGene was employed as the gene
set categories [31].
2.9. Two-dimensional gel electrophoresis analysis
Serum frommicewith orwithout curcumin treatmentwas quantiﬁed
for protein by the bicinchoninic acid (BCA) assay. Two-dimensional gel
electrophoresis (2-DE) analysiswas carried out on aBio-Rad2-DE system
(Bio-Rad Laboratories, Hercules, CA, USA) following the Bio-Rad hand-
book. Protein samples of 75 μg were separated for isoelectric focusing
(IEF) in the ﬁrst dimension using precast immobilized pH gradient strips
(IPG strips, Amersham Pharmacia Biotechnology Inc., New Jersey, USA,
pH range: 3 to 10 linear, 18 cm). Afterwards, the IPG strips were equili-
brated for 15 min with the equilibration solution consisting of 50 mM
Tris–HCl, pH6.8, 6 M urea, 30% glycerol and 2% SDS (Sigma-Aldrich, St.
Louis, MO, USA). 20 mM DTT included in the ﬁrst equilibration solution,
and 2% (w/v) iodoacetamide (Merck, Darmstadt, Germany) was added
in the second equilibration step to alkylate thiols. Subsequently, SDS-
PAGE gels for electrophoresis were applied for the second dimension
based upon Ettan Dalt II system (Amersham Pharmacia Biotechnology
Inc., USA) with the running SDS/Tris buffer consisting with 0.5% agarose
at a constant power (2.5 W/gel for 40 min and 15 W/gel for 6 h) at
room temperature. Gels were stained with silver nitrate based on the
Silver-Staining Plus kit reagent (Amersham Pharmacia Biotechnology
Inc., USA) according to the manufacturer's protocols.
2.10. Image analysis and protein identiﬁcation by ESI-Q-TOP-MS
Stained 2-DE gels were scanned and analyzed using PDQuest soft-
ware (Bio-Rad, Hercules, CA, USA). Signiﬁcantly over-represented pro-
tein spots (p b 0.05 and fold change ≥ 2.0) were excised manually
from gels and dissolved in a digestive solution (0.5% TFA). Proteins of in-
terest were analyzed by an eletrospray ionization quadrupole/time of
ﬂight mass spectrometry (ESI-Q-TOP-MS, Waters, Micromass, Man-
chester, USA). For protein identiﬁcation, analysis was performed using
the Mascot software (http://www.matrixscience.com/). Each experi-
ment was performed in triplicate and results from three independent
experiments were utilized for statistical analysis.
2.11. Molecular docking and dynamics simulation
The molecular docking procedure between NE and curcumin was
appraised using CDOCKER in Discovery Studio™ 2.5 (DS, Accelrys, San
Diego, CA, USA) environment [32]. For ligand preparation, 2-D structure
of curcuminwas produced byKegDrawsoftware. Forceﬁeldwas applied
and binding energywasminimized before the docking procedure. As for
receptor preparation, X-ray crystal structure of NE was downloaded
from the Protein Data Bank (PDB, http://www.rcsb.org/) with the code
number 1B0F. Further, a ligand-based similarity search scheme wasemployed and the docking protocol was performed as a default setting
to avoid a potential reduction in docking accuracy.
Molecular dynamics simulations of NE and curcumin were per-
formed using the standard dynamics cascade protocol in DS. The initial
structures of those two simulations were the results of the ligand-
receptor complexwith the lowest binding energy. The complexwas sol-
vated with water in a cubic box with an explicit periodic boundary
model to stimulate the environment inside the cell. After creating har-
monic restraint, a standard dynamics cascade was performed including
minimization, heating, equilibration and production dynamics.
2.12. Surface plasmon resonance analysis
The in vitro binding afﬁnity assay between NE and curcuminwas ap-
praised by a Biacore 3000 surface plasmon resonance (SPR, Biacore AB,
Uppsala, Sweden). Recombinant human NE (hNE) protein with purity
greater than 98.0% (Catalog number 423681) was purchased from
Merck KGaA (Darmstadt, Germany). Pipelines and chipwere pretreated
with PBS-EP running buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA,
0.005% Surfactant P20 and deionized water, pH 7.4). For SPR analysis,
NE was immobilized on a CM5 sensor chip with pH 5.5. Analysis was
performed at a ﬂow rate of 10 μL/min at 25 °C. Incremental curcumin
doses (7.5, 15, 30, 60 and 120 μM) dissolved in running buffer were
injected into the channels, and binding responses were recorded for
300 s in succession. Binding responses were recorded continuously
with response units (RU) values. The association (ka) and dissociation
(kd) rate constants were elevated by BIA evaluation software (Biacore
AB, Uppsala, Sweden).
2.13. Western blot analysis
Tissues samples were washed twice with chilled PBS and homoge-
nized. After centrifuging and boiling at 100 °C for 5 min, proteins from
total cell lysates were separated by SDS-PAGE and transferred to a
PVDF membrane (Bio-Rad). For Western blot analysis of Akt/p-Akt
(1:1000, Cell Signaling, Beverly, MA, UK), mTOR/p-mTOR (1:1000, Cell
Signaling, Beverly, MA, UK), HIF1α (1:1000, Bioss Biotechnology,
Beijing, China), VEGFR (1:1000, Bioss Biotechnology, Beijing, China),
α1-AT (1:1000, Santa Cruz, CA, USA), NE (1:1000, Santa Cruz, CA,
USA), IRS-1 (1:500, Santa Cruz, CA, USA), GAPDH (1:10,000, Sigma-
Aldrich, St. Louis, MO, USA) and β-actin (1:10,000, Sigma-Aldrich, St.
Louis, MO, USA), the primary antibodies used in the experiment were
probed and incubated overnight at 4 °C, followed by secondary anti-
body reactions with AP-labeled IgG. The detection was evaluated by
the 3-bromo-4-chloro-5-indolyl phosphate (BCIP) and nitro blue tetra-
zolium (NBT) reaction (Amresco, Solon, OH, USA).
2.14. RNA isolation and quantitative real-time PCR
LLC tissues were homogenized, and total RNA was extracted using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The primers used for am-
plifying fragments are as follows: VEGFR (sense primer, 5′-GCCTACCT
CACCTGTTTCCTG-3′); (anti sense primer, 5′-TTGTTCCTGTCTTCCAGAG-
3′), β-actin (sense primer, 5′-TGCGTGACATCAAAGAGAAG-3′); (anti
sense primer, 5′-GATGCCACAGGATTCCATA-3′). For the quantiﬁcation
of VEGFR and β-actin, the cycling protocol consisted of an initial 5 min
denaturation at 95 °C, followed by 45 cycles of denaturation at 95 °C
for 10 s and extension at 60 °C for 1 min. Reactions were performed
using LightCycler (Roche Diagnostics, Mannheim, Germany) with
SYBR™ Green (Perkin-Elmer, Foster City, CA, USA).
2.15. Enzyme-linked immunosorbent assay
After 21 days of treatmentwith curcumin (100 and 300 mg/kg/day),
enzyme-linked immunosorbent assay (ELISA) was performed using a
VEGF ELISA kit (Boster Biotechnology, Wuhan, Hubei, China) per the
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with anti-VEGF mAb and blocked by 5% BSA. 100 μL of the homogenate
including biosamples or standard were added after washing with PBS.
Plates were incubated for 2 h at room temperature and 100 μL of anti-
VEGF polyclonal antibody was added. The reaction was determined on
a Vmax plate reader at 492 nm.
2.16. Statistical analysis
Signiﬁcances of difference between two groups were evaluated by a
Student's unpaired t test and analysis of variance (ANOVA) for compar-
isons among multiple groups using SPSS version 18.0 (SPSS Inc.,
Chicago, IL, USA). All data are expressed as mean ± standard error of
measurement (SEM).Fig. 1. Blood-ﬂow restoration and anti-cancer activity of curcumin in an ischemic hind limbmo
ﬂow restoration in the ischemic hind limb (arrow). (B) Statistical results of blood-ﬂow restorati
of mouse lung. (E) Statistical results for number of metastasis of Lewis Lung cancer. (F) Effect
the survival periods of ischemic insult combined with Lewis Lung cancer xenograft mice mod
and ***p b 0.001 compared with curcumin free group (control).3. Results
3.1. Curcumin supplements blood-ﬂow in the ischemic hind limb, but
suppresses lung cancer progression
To explore the blood-ﬂow restorative capacity of curcumin against
ischemic insult, we ﬁrst quantiﬁed the blood-ﬂow restoration in the is-
chemic hind limb over a 21 day period. Results showed a great viability
of blood-ﬂow recovery capacity, which could be shown to occur in a
dose-response manner as shown in Fig. 1A. During the ﬁrst 7 days,
blood-ﬂow recovered slightly over that of the vehicle. As time went
by, curcumin at both low and high doses signiﬁcantly enhanced
blood-ﬂow in the ischemic hind limb to day 22 (Fig. 1B). The evidence
from laser Doppler blood-ﬂow imaging indicates curcumin candel combined with a Lewis lung cancermodel in the samemouse. (A) Images of the blood-
on assay. (C) Effect of curcumin on tumorweight. (D) Effect of curcumin on thewetweight
of curcumin on Lewis lung cancer volume. (G) Kaplan–Meier curves for an illustration of
el. Data (B)–(E) represent mean ± SEM, n = 8–10 mice per group. *p b 0.05, **p b 0.01
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tions and the high dose group recovers faster than the low dose one.
Meanwhile, we also observed the inﬂuence of curcumin on LLC
growth. Fig. 1C showed that curcumin signiﬁcantly impaired lung can-
cer growth dose-dependently by day 22 (p b 0.05). Meanwhile, lung
netweight (Fig. 1D), number of pulmonarymetastases (Fig. 1E) andpri-
mary tumor volume (Fig. 1F) also dramatically decreasedwith curcumin
administration. In addition, change of survival rate was effectively en-
hanced by curcumin, as evidenced by a 29% increase (300 mg/kg
curcumin group) over that of the vehicle on day 21 (Fig. 1G). Thus,Fig. 2.Representative CD31 immunohistochemistry images for capillary density (arrow). (A) Im
cle tissues. (B) Images of immunohistological assay and statistical result of CD31 expression in p
and ***p b 0.001 compared with the curcumin free group (control). Original magniﬁcation ×2considered together, this data indicates the inhibitory role of curcumin
on lung cancer in ischemia and LLC bearing mice.
3.2. Curcumin increases ischemic muscle microvessel density, but retards
lung cancer angiogenesis
To assesswhether curcuminwould stimulate or inhibit angiogenesis
in the ischemia and lung cancer mouse model, freshly resected cancer
tissues and ischemic muscles were examined using CD31 staining.
Oral administration of curcumin at 300 mg/kg/day signiﬁcantlyages of immunohistological assay and statistical result of CD31 expression in ischemicmus-
rimary Lewis lung cancer tissues. Data represent mean± SEM, n= 6. *p b 0.05, **p b 0.01
50 (scale bars: 20 μm).
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the positive area in Fig. 2A. In contrast, curcumin impaired capillary re-
generation in cancer tissues, as indicated by a 74.8% decrease (Fig. 2B).
In brief, these observations are compatible with the notion that
curcumin administration can stimulate post-ischemic revascularization
and inhibit angiogenesis against primary LLC synchronously.3.3. HUVEC and CAM exhibit differential sensitivities to curcumin
To investigate the in vitro angiogenic responses, we treated HUVEC
with increasing concentrations of curcumin, from 0.01 to 30 μM for 24
h. Striking variations on HUVEC were observed as shown in Fig. 3A
and B. In the presence of concentrations from 0.1 to 0.3 μM, capillary-
like tube length concentration-dependently increased after curcumin
treatment. Whereas, curcumin reversed these alternations dramatically
within the scope of 3 to 10 μM.
In order to further elaborate neovascularization with or without
curcumin treatment, we additionally performed chicken CAM assays
in vivo. Fig. 3C and D shows the digitized representations of emblemat-
ical CAM treated for 72 h with curcumin. Results indicated the number
of small blood vessels increased signiﬁcantly within the dosage range of
1 to 3 μM. In contrast, in the presence of 10 to 30 μM, a dose-speciﬁcFig. 3. Effect of curcumin on HUVEC tube formation and CAM neovascularization. (A) Capillary-
assay onHUVEC. (C) CAM assay of curcumin on neovascularization (arrow). (D) Statistical resul
*p b 0.05, **p b 0.01 and ***p b 0.001 compared with the curcumin free group (control). Osuppression of blood vessel regeneration occurred. In short, our results
reveal the Janus face of curcumin on tube formulation and neovascular-
ization as a function of dose.3.4. Curcumin negatively or positively regulates the HIF1α/mTOR/VEGF/
VEGFR cascade in ischemic muscle and primary LLC tissues, respectively
We next sought to address the speciﬁc signaling pathways affected
by curcumin in ischemic muscles and LLC xenograft tissues in the
mousemodel simultaneously. Ourmodel for the construction of the pri-
mary GRNs was based on the utilization of interaction from target pre-
diction. As of June 2012, the list contained 3,494 and 7,064 nodes in
ischemia and lung cancer, respectively (Rawdatawere appended in Ad-
ditional ﬁle). Starting from the gene association network based on
PubMed, Agilent LitSearch tool created two biologically relevant projec-
tions (Fig. 4A and B). After intersecting with NetworkMerge plugin, the
overlapped genes entangled in ischemia and lung cancerwere clustered
by MCODE algorithm (Fig. 4C).
Genes in disease-associated communities always share similarities
in which they are inclined to connect. This dense clique within a
network is regarded as GRNs. As shown in Fig. 4D to G, with the higher
degree of gene regulation, we inferred the underlying biologicallike tube formulation (arrow) assay of curcumin. (B) Statistical results of tube formulation
ts of tube formulation assay on HUVEC. Data (B) and (D) represent mean± SEM, n= 3.
riginal magniﬁcation ×400.
Fig. 4. Visualization of human disease-gene interaction networks (Force-Directed Layout) and pathway enrichment analysis result. (A) Ischemia network contains 1,836 nodes and 8,286
edges. (B) Lung cancer network contains 3,171 nodes and 17,439 edges. (C) The overlapped genes between ischemia and lung cancer data (Grid Layout). Intersections of gene sets com-
prised 1,234 nodes and 1,488 edges. (D)–(G) Gene regulatory networks (GRNs) obtain from the overlapped genes. Gene-sets fail to pass the enrichment cluster score threshold of 2.0 are
not shown. Each node (represents as a circle)matches to a gene, and edges represent interactions of nodes: red represents high degree connectivity, whereas green represents low degree
connectivity. The size of each node is proportionate to the degree. (H) Pathway enrichment analysis results of the overlapped GRNs based on ToppFun (FDR b 0.05).
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tions. As presented in Fig. 4H, the enriched signaling pathways inmulti-
ple categories were selected with a FDR threshold less than 0.05, which
indicated cytokine–cytokine receptor interaction, S1P3 pathway, VEGFR
speciﬁc signals, mTOR signaling pathway, Focal adhesion, HIF1α tran-
scription factor network and genes involved in signaling by VEGF
might play decisive roles in ischemia and lung cancer simultaneously.
To explain the dual phenotype obtained from the in vivo and in vitro
ﬁndings, and increase our understanding of the underlying mecha-
nisms, we conducted a series of Western blot, real-time PCR and ELISA
analysis with or without curcumin treatment. Our data revealed that
curcumin increased HIF1α, p-mTOR/mTOR, VEGF and VEGFR in ische-
mic muscles, but reversed these alternations, as indicated by 50% to
100% decrease in the primary LLC tissues (Fig. 5). Thus, consistent
with the in silico prediction, our data strongly suggest that the dual an-
giogenic effects of curcumin in ischemic insult and primary lung cancer
are mediated by the HIF1α/mTOR/VEGF/VEGFR cascade but in the op-
posite fashion.
3.5. α1-AT is a serum biomarker for ischemia and LLC mice model
In mice exposed to 300 mg/kg curcumin, two differently expressed
proteins regulated by curcuminwere detected by 2-DE (Fig. 6A). As pre-
sented in Fig. 6B to D, α1-AT (spot 1) and transthyretin (TTR, spot 2)
were identiﬁed via sequence analysis, using ESI-Q-TOP-MS and data-
base retrieval. Since an imbalance of NE and α1-AT was a risk factorfor malignant initiation and progression, the down-regulation of α1-
AT in mouse serum was of interest and deserved further investigation
[33,34].
3.6. Curcumin increases α1-AT production, but blocks NE release in
LLC tissues
Aberrant expression of NE is associatedwith tumor initiation [35]. In
mice with ischemia and lung cancer, obvious expression of NE was ob-
served in primary lung cancer tissues. Curcumin dramatically reversed
the inﬂammatory alternations seen for α1-AT and NE in LLC tissues
(Fig. 6E to G). In fact, α1-AT secretion was remarkably increased after
curcumin treatment at both low and high doses. Of note, neither of
the two proteins could be detected in ischemicmuscles with or without
curcumin treatment (data not shown). Thus, our data suggest that the
pernicious effects of NE on lung cancer angiogenesis are abolished by
treatment with curcumin.
3.7. IRS-1 protein is upregulated in the primary lung cancer tissues after
curcumin treatment
It has been documented that NE can promote the degradation of in-
sulin receptor substrate-1 (IRS-1) protein and accelerate lung cancer
growth [36], as IRS-1 is a key regulator of PI3Kwithin variousmalignan-
cies. In the present study, we discovered that curcumin signiﬁcantly
promoted IRS-1 expression in the lung cancer tissues compared to the
Fig. 5. Curcumin differently regulated VEGFR/mTOR/HIF1α/VEGF cascade in ischemia and LLCmodel. (A) Images of Western blot analysis of HIF1α, pAkt/Akt, p-mTOR/mTOR and VEGFR
expression levels in the ischemic muscles. (B)–(E) Statistical analysis of Western blot for HIF1α, pAkt: Akt ratio, p-mTOR: mTOR ratio and VEGFR in the ischemic muscles. (F) Statistical
analysis of ELISA for VEGF in the ischemicmuscles. (G) Images of Western blot analysis of HIF1α, pAkt/Akt and p-mTOR/mTOR expression levels in the primary Lewis lung cancer tissues.
(H)–(J) Statistical analysis ofWestern blot forHIF1α, pAkt: Akt ratio andp-mTOR:mTOR ratio in the primary Lewis lung cancer tissues. (K) Statistical analysis of quantitative real-time PCR
for VEGFRmRNA in the primary Lewis lung cancer tissues. (L) Statistical analysis of ELISA for VEGF in the primary Lewis lung cancer tissues. Data representmean± SEM, n= 6. *p b 0.05,
**p b 0.01 and ***p b 0.001 compared with the curcumin free group (control).
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is able to promote IRS-1 expression in the primary lung cancer tissues
via downregulation of NE.
3.8. NE is identiﬁed as a direct protein-target for curcumin
To investigate the interaction of NE and curcumin, speciﬁc binding of
curcumin to hNE was conducted by molecular dynamics study and SPR
analysis. The in silico drug target docking modeling analysis indicatedthat curcumin could directly cage into the binding pocket of NE
(Fig. 7A to C) with 27.4099 kcal/mol in its best binding pose. As
shown in Fig. 7B, both ARG178 and ARG217 play decisive roles in H-
bond formation, which contributed to stabilizing the complex of NE
and curcumin. The RMSD reference of curcumin, plotted in Fig. 7D,
showed that the interaction of the receptor-ligand complex reached
the equilibrium state after 7 s. A similar situation could be observed in
the interaction analysis between the O of curcumin and HH in the
amino residue of Arg178 and ARG217 in NE (Fig. 7E and F). All the
Fig. 6. Proteomics identiﬁcation of proteins differentially expressed in mice serum obtained from ischemic insult collaborated with lung cancer mice model before and after curcumin
treatment. (A) Two-dimensional gel electrophoresis (2-DE) images of serum proteins in the presence of curcumin (300 mg/kg/day) or vehicle. Gel pair is the representative images of
six replicate gels obtained from three independent experiments. Differentially expressed spots are pointed out by the arrows. (B) Expanded regions of the differentially expressed protein
spots (circles). (C) Result of ESI-Q-TOP-MS analysis ofα1-antitrypsin (α1-AT, as spot 1). (D) Result of ESI-Q-TOP-MS analysis of transthyretin (TTR, as spot 2). (E) Images of Western blot
analysis ofα1-AT, NE and IRS-1protein expression levels in theprimary Lewis lung cancer tissues. (F) Statistical analysis ofWestern blot forα1-AT in the primary Lewis lung cancer tissues.
(G) Statistical analysis of Western blot for NE in the primary Lewis lung cancer tissues. (H) Statistical analysis of Western blot for IRS-1 in the primary Lewis lung cancer tissues. Data
(F)–(H) represent mean ± SEM, n = 6. *p b 0.05 , **p b 0.01 and ***p b 0.001compared with the curcumin free group (control).
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results suggest that these two residues of the catalytic site can stabilize
the interaction between curcumin and NE.
Further, we additionally investigated the binding afﬁnity of curcumin
towards NE based on SPR. As presented in Fig. 7G, response units (RU)
values signiﬁcantly increased with the incremental curcumin doses
from 7.5 to 120 μM, indicating curcumin could directly bind to NE in a
concentration-dependent manner. The association (ka) and dissociation
(kd) rate constants of curcumin binding to the immobilized NE on a
CM5 chipwere 275M−1 s−1 and 8.73× 10−3 s−1, respectively. The equi-
librium dissociation constant (KD= kd/ka) was 3.17 × 10−5 M. These re-
sults mentioned above conﬁrm NE is a direct target for curcumin.
4. Discussion
In the present study, we discovered that curcumin accelerated blood
ﬂow restoration and promoted post-ischemic revascularization. In con-
trast, NE secretion beneﬁted lung cancer progression, but this alterna-
tion was reversed by curcumin. Thus, the present results demonstrate
the opposite effect of curcumin on angiogenesis in ischemia and LLC
growth in a simultaneous mouse model.
According to the recent publications, the availability of proteomics
approach has been widely utilized in the discovery of disease bio-
markers [37–39]. To better elucidate the opposite angiogenesis actionmediated by curcumin in vivo, we ﬁrst performed 2-DE in mouse
serum and discovered that oral administration of curcumin decreased
α1-AT secretion. Other investigations have demonstrated α1-AT was
decreased remarkably in a variety of malignancies, especially lung can-
cer [40–43]. Imbalance of NE and α1-AT was considered as a risk
factor for lung cancer progression. A recent work reported that NE and
α1-AT were involved in lung cancer proliferation. It was found that in
vitro hNE treatment of human A549 and Calu-3 lung cancer cells mim-
icked cell proliferation as seen in the LLC xenograft mousemodel. In ad-
dition, curcumin decreased endogenous and/or exogenous NE
production, which in turn, retarded tumor growth in primary lung can-
cer tissues [44]. Thus, consistent with this previous report, our data fur-
ther conﬁrm NE can stimulate lung cancer angiogenesis and curcumin
can reverse this undesirable action mediated by NE.
Inference GRNs using the target prediction method deepened our
understanding genes associated with illnesses. To further elucidate the
underlyingmechanismsmediated by curcumin,we enriched the signal-
ing pathways involved in ischemia and lung cancer. Among them,
VEGFR speciﬁc signals, mTOR signaling pathway, HIF1α transcription
factor network and genes involved in signaling by VEGF have been
shown to be highly associatedwith ischemic insult and lung cancer syn-
chronously. These ﬁndings are consistent with the incremental evi-
dences for the involvement of HIF1α, mTOR, VEGF and VEGFR in
ischemia and lung cancer [45].
Fig. 7. Protein-ligand interaction, molecular dynamics and binding afﬁnity studies of NE and curcumin. (A) Interaction models of NE and curcumin in the best docking pose. (B) Detailed
interaction modes of NE and curcumin in the best docking pose. (C)Model of NE and curcumin in solvent. (D) Drug positional RMSD. (E) Interaction bond energy of amino residue group
betweenNE and curcumin. (F) Interaction energy of amino residue group betweenNE and curcumin through all themolecular dynamics. Curcumin is in the stick representation,while the
residues of NE are presented by solid style in the line representation. Hydrogen bonds are depicted by green dotted lines.Water is depicted by pink. C, H, and O are colored in gray, white,
and red, respectively. (G) Real time binding afﬁnitymeasurements of curcumin using Biacore 3000. Representative sensorgrams are obtained from the injections of curcumin at different
concentrations of 120, 60, 30, 15, and 7.5 μM (curve from top to bottom) over the immobilized NE surface on the CM5 chip.
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rin and acted via their afﬁnity transmembrane receptors VEGFR1 and
VEGFR2, VEGF is a fundamental molecular regulator of angiogenesis
[46]. Studies have reported that there was a strong local production of
VEGF in lungs of patients with lung cancer and the up-regulation of
VEGF has been found in highly-malignant cancer [47]. As mentioned,
various anti-angiogenic avenues to block VEGF in cancer are under de-
velopment [48]. Bevacizumab (Avastin), a VEGF-neutralizing antibody,
has been recommended and approved by theUS Food andDrug Admin-
istration for several metastatic cancers. Besides, treatment with other
VEGF inhibitors also prolonged the survival of cancer patients as sum-
marized by Carmeliet et al. [49]. The clinical use of VEGF blockade for
anti-angiogenic therapy, however, is still not optimistic owing to its cy-
totoxicity and poor selectivity [50]. In this present study, we examined
the concentrations of VEGF in lung cancer and ischemic muscles and
discovered VEGF concentrations distributed in lung cancer were much
higher than the ischemic tissues. As a natural product with great safetyand low toxicity, curcumin could efﬁciently inhibit vascularization via
downregulation of VEGF in lung cancer.With regard to ischemic tissues,
VEGF contentswere signiﬁcantly increased, resulting in pro-angiogenesis.
Although the clinical signiﬁcance of curcumin for angiogenesis is contro-
versial, the beneﬁcial effects could be seen in the ischemia and lung
cancer mice model.
In response to VEGF, activation of VEGFR contributes to stimulating
angiogenesis. Thus, further studies on VEGF/VEGFR axis facilitate our
understanding of the physiological process involved in ischemia and
allow us to put forward a proposal to retard angiogenesis in lung cancer.
Emerging evidences indicate that VEGF exerts protective effects against
acute myocardial ischemia through stimulation of VEGFR2 [51]. The
mechanism by which curcumin mediates ischemic angiogenesis re-
mains unknown. In our study, the upregulation of VEGFR2 in the ische-
mic tissueswas corroborated byWestern blot after curcumin treatment.
However, therewasno signiﬁcant alternation of VEGFR2 protein level in
lung cancer in the presence and absence of curcumin. The signiﬁcant
1752 S. Fan et al. / Biochimica et Biophysica Acta 1842 (2014) 1742–1754decrease of VEGFR mRNA did not cohere with the recent ﬁndings in
pancreatic cancer cell, which indicated that the anti-proliferative effect
of curcumin took effect via downregulation of VEGFR protein expres-
sion [52]. This difference may be contributed to the variation of cancer
cell type.
Recently, Sidhu et al. [53] reported that curcumin could accelerate
wound healing in diabetic mice after topical application by repairing
collagen, hexosamine and damaged DNA. Meanwhile, without serum,
curcumin induced EC differentiation, increased capillary vessel density
in CAM, and promoted morphological alterations of pro-angiogenic
phenotype on HUVEC via elevation of CD31, E-selectin, VEGF and
VEGFR2 production. In contrast, under serum stimulated conditions,
curcumin revealed an anti-angiogenic effect on EC, CAM and HUVEC
through negative control of angiogenic factors. It was conﬁrmed that
curcumin treatment could distinguish between normal and abnormal
cells, and create recognizable angiogenesis in different cellularmicroen-
vironments [54]. Consistent with the conclusion mentioned above, in
the present study, our data in vitro show that curcumin reveals opposite
angiogenic effects on HUVEC and chicken CAM as a function of dose.
Interestingly, biphasic dose responses of curcumin on revasculariza-
tion have been frequently observed i.e. low levels of curcumin have an
angiogenesis stimulating effect while higher doses inhibit angiogenesis
[55]. Thaloor et al. [56] discovered that curcumin revealed a pro-
angiogenic effect at a low therapeutic concentration (20 mg/kg/day),
whereas it suppressed tumor progression in the high dose groupsFig. 8. Schematic diagramof curcumin regulatory pathway against ischemic insult and Lewis lun
esized to occur through the binding and reactingwith VEGFR speciﬁc signaling pathway, mTOR
diagram shows that curcumin promotes the expression of hub-proteins, resulting in vascular
endogenous NE secretion and rebalanced the equilibriums ofα1-AT and NE in lung cancer tissu
of relevant proteins in the HIF1α/mTOR/VEGF/VEGFR cascade and inhibits LLC progression of t(100 to 300 mg/kg/day) in C57BL/6 mice [44]. Whether stimulatory
and/or inhibitory responsiveness would occur in a combined ischemic
insult and lung cancer model to curcumin, as described in low and
high doses in vivo studies, was not known. Interestingly, our present
study discloses that curcumin can retard tumor growth by decreasing
NE secretion. Meanwhile, it also reveals a dual angiogenic outcome
in a simultaneous mouse model with ischemia and LLC. Inﬂamma-
tion is highly associated with cancer initiation and progression. Mo-
lecular mechanisms about how curcumin gives rise to opposite
angiogenic effects in such a murine mouse model might be attribut-
ed to the inﬂammatory activity of NE in the microenvironment of
lung cancer. Brieﬂy, curcumin distributed in ischemic hind limb pro-
motes post-ischemic neovascularization via activation of the HIF1α/
mTOR/VEGF/VEGFR cascade [57]. In contrast, in the LLC tissues,
curcumin reveals an inhibitory phenotype by directly binding to NE
causing a disequilibrium between α1-AT and NE, which subsequently
gives rise to the anti-tumorigenic effect in the primary lung cancer tis-
sues. Dual angiogenic mechanisms evoked by curcumin are presented
in a simpliﬁed model (Fig. 8).
In summary, themain ﬁndings of the present experimentwere that:
(1) curcumin caused opposite angiogenic effects in an ischemic insult
model and LLC mouse tumor model in the same mouse; (2) Janus
faced angiogenic effects mediated by curcumin in this model relied on
the HIF1α/mTOR/VEGF/VEGFR cascade; (3) curcumin could reverse
the angiogenic effect mediated by NE in lung cancer tissues; and (4)g cancer synchronously. Angiogenesis of curcumin against ischemic hind limbwas hypoth-
pathway, HIF1α transcription factor network and genes involved in signaling by VEGF. The
regeneration in response to ischemic insult. Contrarily, curcumin in lung cancer reduces
es via direct interaction with NE. This action subsequently down-regulates the expression
he ischemia and Lewis lung carcinoma mice model.
1753S. Fan et al. / Biochimica et Biophysica Acta 1842 (2014) 1742–1754the favorable angiogenic effects of curcumin could in part beneﬁt indi-
viduals who suffer from both ischemic disorders and lung cancer.
Conﬂict of interest statement
The authors declare that they have no competing interests.
Acknowledgements
Wewould like to thank Dr Liangren Zhang of the State Key Laborato-
ry of Natural and Biomimetic Drugs of Peking University Health Science
Center for guiding the molecular docking and dynamics studies. This
work was supported by the National Natural Science Foundation of
China (No. 91129727, 81020108031, 30973558, 81270049, 81373405)
and Research Fund from Ministry of Education of China (111 Projects
No. B07001). The funders had no role in study design, data collection
and analysis, decision to publish, or in the preparation of themanuscript.
Appendix A
List of the signiﬁcant genetic genes involved in ischemia and lung
cancer screened from OMIM, GAD and GeneCard databases.
References
[1] G. Zerbini, M. Lorenzi, A. Palini, Tumor angiogenesis, N. Engl. J. Med. 359 (2008)
763–764.
[2] E. Duh, L.P. Aiello, Vascular endothelial growth factor and diabetes: the agonist ver-
sus antagonist paradox, Diabetes 48 (1999) 1899–1906.
[3] B. Witzenbichler, T. Asahara, T. Murohara, M. Silver, I. Spyridopoulos, M. Magner, N.
Principe, M. Kearney, J.S. Hu, J.M. Isner, Vascular endothelial growth factor-C (VEGF-
C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia, Am. J. Pathol.
153 (1998) 381–394.
[4] Z.G. Zhang, L. Zhang, Q. Jiang, R. Zhang, K. Davies, C. Powers, N. Bruggen, M. Chopp,
VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the is-
chemic brain, J. Clin. Invest. 106 (2000) 829–838.
[5] D. Lambrechts, E. Storkebaum, M. Morimoto, J. Del-Favero, F. Desmet, S.L. Marklund,
S. Wyns, V. Thijs, J. Andersson, I. van Marion, A. Al-Chalabi, S. Bornes, R. Musson, V.
Hansen, L. Beckman, R. Adolfsson, H.S. Pall, H. Prats, S. Vermeire, P. Rutgeerts, S.
Katayama, T. Awata, N. Leigh, L. Lang-Lazdunski, M. Dewerchin, C. Shaw, L. Moons,
R. Vlietinck, K.E. Morrison, W. Robberecht, C. Van Broeckhoven, D. Collen, P.M.
Andersen, P. Carmeliet, VEGF is a modiﬁer of amyotrophic lateral sclerosis in mice
and humans and protects motoneurons against ischemic death, Nat. Genet. 34
(2003) 383–394.
[6] P. Carmeliet, Angiogenesis in health and disease, Nat. Med. 9 (2003) 653–660.
[7] A. Rapisarda, G. Melillo, Role of the VEGF/VEGFR axis in cancer biology and therapy,
Adv. Cancer Res. 114 (2012) 237–267.
[8] H.S. Kim, Do not put too much value on conventional medicines, J. Ethnopharmacol.
100 (2005) 37–39.
[9] G. Bar-Sela, R. Epelbaum, M. Schaffer, Curcumin as an anti-cancer agent: review of
the gap between basic and clinical applications, Curr. Med. Chem. 17 (2010)
190–197.
[10] C. Rozzo, M. Fanciulli, C. Fraumene, A. Corrias, T. Cubeddu, I. Sassu, S. Cossu, V.
Nieddu, G. Galleri, E. Azara, M.A. Dettori, D. Fabbri, G. Palmieri, M. Pisano, Molecular
changes induced by the curcumin analogue D6 in humanmelanoma cells, Mol. Can-
cer 12 (2013) 37.
[11] A.S. Strimpakos, R.A. Sharma, Curcumin: preventive and therapeutic properties in
laboratory studies and clinical trials, Antioxid. Redox Signal. 10 (2008) 511–545.
[12] S. Miriyala, M. Panchatcharam, P. Rengarajulu, Cardioprotective effects of curcumin,
Adv. Exp. Med. Biol. 595 (2007) 359–377.
[13] G. Srivastava, J.L. Mehta, Currying the heart: curcumin and cardioprotection, J.
Cardiovasc. Pharmacol. Ther. 14 (2009) 22–27.
[14] Z.J. Sun, G. Chen, W. Zhang, X. Hu, Y. Liu, Q. Zhou, L.X. Zhu, Y.F. Zhao, Curcumin du-
ally inhibits both mammalian target of rapamycin and nuclear factor-kappaB path-
ways through a crossed phosphatidylinositol 3-kinase/Akt/IkappaB kinase complex
signaling axis in adenoid cystic carcinoma, Mol. Pharmacol. 79 (2011) 106–118.
[15] S.S. Lin, K.C. Lai, S.C. Hsu, J.S. Yang, C.L. Kuo, J.P. Lin, Y.S. Ma, C.C. Wu, J.G. Chung,
Curcumin inhibits the migration and invasion of human A549 lung cancer cells
through the inhibition of matrix metalloproteinase-2 and−9 and vascular endo-
thelial growth factor (VEGF), Cancer Lett. 285 (2009) 127–133.
[16] D.G. Binion, M.F. Otterson, P. Raﬁee, Curcumin inhibits VEGF-mediated angiogenesis
in human intestinal microvascular endothelial cells through COX-2 and MAPK inhi-
bition, Gut 57 (2008) 1509–1517.
[17] Y.T. Tung, H.L. Chen, C.W. Lai, C.J. Shen, Y.W. Lai, C.M. Chen, Curcumin reduces pul-
monary tumorigenesis in vascular endothelial growth factor (VEGF)-overexpressing
transgenic mice, Mol. Nutr. Food Res. 55 (2011) 1036–1043.[18] G. Chakraborty, S. Jain, S. Kale, R. Raja, S. Kumar, R. Mishra, G.C. Kundu, Curcumin
suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF ex-
pression, Mol. Med. Rep. 1 (2008) 641–646.
[19] G. Hansen, H. Gielen-Haertwig, P. Reinemer, D. Schomburg, A. Harrenga, K. Nieﬁnd,
Unexpected active-site ﬂexibility in the structure of human neutrophil elastase in
complex with a new dihydropyrimidone inhibitor, J. Mol. Biol. 409 (2011) 681–691.
[20] P. Shamamian, J.D. Schwartz, B.J. Pocock, S. Monea, D. Whiting, S.G. Marcus, P.
Mignatti, Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin
G, and proteinase-3: a role for inﬂammatory cells in tumor invasion and angiogen-
esis, J. Cell. Physiol. 189 (2001) 197–206.
[21] D.H. Perlmutter, Alpha-1-antitrypsin deﬁciency: biochemistry and clinical manifes-
tations, Ann. Med. 28 (1996) 385–394.
[22] R. Mohan, J. Sivak, P. Ashton, L.A. Russo, B.Q. Pham, N. Kasahara, M.B. Raizman, M.E.
Fini, Curcuminoids inhibit the angiogenic response stimulated by ﬁbroblast growth
factor-2, including expression of matrix metalloproteinase gelatinase B, J. Biol.
Chem. 275 (2000) 10405–10412.
[23] P. Yoysungnoen, P. Wirachwong, P. Bhattarakosol, H. Niimi, S. Patumraj, Effects of
curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellu-
lar carcinoma cell-implanted nude mice, Clin. Hemorheol. Microcirc. 34 (2006)
109–115.
[24] S. Brandon, Ethics, economics and science, J. R. Soc. Med. 84 (1991) 575–577.
[25] M. Sata, H. Nishimatsu, J. Osuga, K. Tanaka, N. Ishizaka, S. Ishibashi, Y. Hirata, R.
Nagai, Statins augment collateral growth in response to ischemia but they do not
promote cancer and atherosclerosis, Hypertension 43 (2004) 1214–1220.
[26] Y. Yamashita-Kashima, K. Fujimoto-Ouchi, K. Yorozu, M. Kurasawa, M. Yanagisawa,
H. Yasuno, K. Mori, Biomarkers for antitumor activity of bevacizumab in gastric can-
cer models, BMC Cancer 12 (2012) 37.
[27] K. Kunimasa, T. Ohta, H. Tani, E. Kato, R. Eguchi, K. Kaji, K. Ikeda, H. Mori, M. Mori, T.
Tatefuji, Y. Yamori, Resveratrol derivative-rich Melinjo (Gnetum gnemon L.) seed ex-
tract suppresses multiple angiogenesis-related endothelial cell functions and tumor
angiogenesis, Mol. Nutr. Food Res. 55 (2011) 1730–1734.
[28] D. Ribatti, Chick embryo chorioallantoic membrane as a useful tool to study angio-
genesis, Int. Rev. Cell Mol. Biol. 270 (2008) 181–224.
[29] A. Vailaya, P. Bluvas, R. Kincaid, A. Kuchinsky, M. Creech, A. Adler, An architecture for
biological information extraction and representation, Bioinformatics 21 (2005)
430–438.
[30] G.D. Bader, C.W. Hogue, An automated method for ﬁnding molecular complexes in
large protein interaction networks, BMC Bioinformatics 4 (2003) 2.
[31] J. Chen, E.E. Bardes, B.J. Aronow, A.G. Jegga, ToppGene Suite for gene list enrichment
analysis and candidate gene prioritization, Nucleic Acids Res. 37 (2009)
W305–W311.
[32] S. Fan, Q. Geng, Z. Pan, X. Li, L. Tie, Y. Pan, X. Li, Clarifying off-target effects for
torcetrapib using network pharmacology and reverse docking approach, BMC
Syst. Biol. 6 (2012) 152.
[33] R.F. Machado, D. Laskowski, O. Deffenderfer, T. Burch, S. Zheng, P.J. Mazzone, T.
Mekhail, C. Jennings, J.K. Stoller, J. Pyle, J. Duncan, R.A. Dweik, S.C. Erzurum, Detec-
tion of lung cancer by sensor array analyses of exhaled breath, Am. J. Respir. Crit.
Care Med. 171 (2005) 1286–1291.
[34] B. Hamrita, K. Chahed, M. Trimeche, C.L. Guillier, P. Hammann, A. Chaieb, S. Korbi, L.
Chouchane, Proteomics-based identiﬁcation of alpha1-antitrypsin and haptoglobin
precursors as novel serum markers in inﬁltrating ductal breast carcinomas, Clin.
Chim. Acta 404 (2009) 111–118.
[35] Z. Sun, P. Yang, Role of imbalance between neutrophil elastase and alpha 1-
antitrypsin in cancer development and progression, Lancet Oncol. 5 (2004)
182–190.
[36] A.M. Houghton, D.M. Rzymkiewicz, H. Ji, A.D. Gregory, E.E. Egea, H.E. Metz, D.B. Stolz,
S.R. Land, L.A. Marconcini, C.R. Kliment, K.M. Jenkins, K.A. Beaulieu, M. Mouded, S.J.
Frank, K.K. Wong, S.D. Shapiro, Neutrophil elastase-mediated degradation of IRS-1
accelerates lung tumor growth, Nat. Med. 16 (2010) 219–223.
[37] R.R. Drake, L.H. Cazares, E.E. Jones, T.W. Fuller, O.J. Semmes, C. Laronga, Challenges to
developing proteomic-based breast cancer diagnostics, OMICS 15 (2011) 251–259.
[38] B.L. Adam, A. Vlahou, O.J. Semmes, G.J. Wright, Proteomic approaches to biomarker
discovery in prostate and bladder cancers, Proteomics 1 (2001) 1264–1270.
[39] E.T. Fung, G.J. Wright, E.A. Dalmasso, Proteomic strategies for biomarker identiﬁca-
tion: progress and challenges, Curr. Opin. Mol. Ther. 2 (2000) 643–650.
[40] Z.J. El-Akawi, F.K. Al-Hindawi, N.A. Bashir, Alpha-1 antitrypsin (alpha1-AT) plasma
levels in lung, prostate and breast cancer patients, Neuro. Endocrinol. Lett. 29
(2008) 482–484.
[41] V. Urquidi, S. Goodison, S. Ross, M. Chang, Y. Dai, C.J. Rosser, Diagnostic potential of
urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer, J.
Urol. 188 (2012) 2377–2383.
[42] N. Maurice, D.H. Perlmutter, Novel treatment strategies for liver disease due to
alpha1-antitrypsin deﬁciency, Clin. Transl. Sci. 5 (2012) 289–294.
[43] Z.J. El-Akawi, A.M. Abu-Awad, A.M. Sharara, Y. Khader, The importance of alpha-
1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-
small cell lung and prostate cancer patients, Neuro. Endocrinol. Lett. 31 (2010)
113–116.
[44] Y. Xu, J. Zhang, J. Han, X. Pan, Y. Cao, H. Guo, Y. Pan, Y. An, X. Li, Curcumin inhibits
tumor proliferation induced by neutrophil elastase through the upregulation of
alpha1-antitrypsin in lung cancer, Mol. Oncol. 6 (2012) 405–417.
[45] K. Deacon, D. Onion, R. Kumari, S.A. Watson, A.J. Knox, Elevated SP-1 transcription
factor expression and activity drives basal and hypoxia-induced vascular endotheli-
al growth factor (VEGF) expression in non-small cell lung cancer, J. Biol. Chem. 287
(2012) 39967–39981.
[46] M. Shibuya, Structure and function of VEGF/VEGF-receptor system involved in an-
giogenesis, Cell Struct. Funct. 26 (2001) 25–35.
1754 S. Fan et al. / Biochimica et Biophysica Acta 1842 (2014) 1742–1754[47] A. Rozman, M. Silar, M. Kosnik, Angiogenin and vascular endothelial growth factor
expression in lungs of lung cancer patients, Radiol. Oncol. 46 (2012) 354–359.
[48] R.K. Jain, D.G. Duda, J.W. Clark, J.S. Loefﬂer, Lessons from phase III clinical trials on
anti-VEGF therapy for cancer, Nat. Clin. Pract. Oncol. 3 (2006) 24–40.
[49] P. Carmeliet, R.K. Jain, Molecular mechanisms and clinical applications of angiogen-
esis, Nature 473 (2011) 298–307.
[50] R.K. Jain, D.G. Duda, C.G.Willett, D.V. Sahani, A.X. Zhu, J.S. Loefﬂer, T.T. Batchelor, A.G.
Sorensen, Biomarkers of response and resistance to antiangiogenic therapy, Nat.
Rev. Clin. Oncol. 6 (2009) 327–338.
[51] E.Messadi, Z. Aloui, E. Belaidi,M.P. Vincent, E. Couture-Lepetit, L.Waeckel, J. Decorps,
N. Bouby, A. Gasmi, H. Karoui, M. Ovize, F. Alhenc-Gelas, C. Richer, Cardioprotective
effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice:
effect on mitochondrial function, J. Cardiovasc. Pharmacol. 63 (2014) 274–281.
[52] I. Jutooru, G. Chadalapaka, P. Lei, S. Safe, Inhibition of NFkappaB and pancreatic can-
cer cell and tumor growth by curcumin is dependent on speciﬁcity protein down-
regulation, J. Biol. Chem. 285 (2010) 25332–25344.[53] G.S. Sidhu, H. Mani, J.P. Gaddipati, A.K. Singh, P. Seth, K.K. Banaudha, G.K. Patnaik, R.
K. Maheshwari, Curcumin enhances wound healing in streptozotocin induced dia-
betic rats and genetically diabetic mice, Wound Repair Regen. 7 (1999) 362–374.
[54] M.S. Kiran, V.B. Kumar, R.I. Viji, G.T. Sherin, K.N. Rajasekharan, P.R. Sudhakaran, Op-
posing effects of curcuminoids on serum stimulated and unstimulated angiogenic
response, J. Cell. Physiol. 215 (2008) 251–264.
[55] R.K. Maheshwari, A.K. Singh, J. Gaddipati, R.C. Srimal, Multiple biological activities of
curcumin: a short review, Life Sci. 78 (2006) 2081–2087.
[56] D. Thaloor, K.J. Miller, J. Gephart, P.O. Mitchell, G.K. Pavlath, Systemic administration
of the NF-kappaB inhibitor curcumin stimulatesmuscle regeneration after traumatic
injury, Am. J. Physiol. 277 (1999) C320–C329.
[57] R. Li, X. Qiao, Q. Li, R. He, M. Ye, C. Xiang, X. Lin, D. Guo, Metabolic and pharmacoki-
netic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin inmice
tumor after intragastric administration of nanoparticle formulations by liquid chro-
matography coupled with tandem mass spectrometry, J. Chromatogr. B Anal.
Technol. Biomed. Life Sci. 879 (2011) 2751–2758.
